In keeping with their promising and favorable hemodynamic effects, a recent meta-analysis of 11 trials reporting on SCD in patients receiving SGLT2 inhibitors, indicated that these agents seem to have a favorable effect on SCD [177]. The gene discussed is SLC5A2; the disease is Schnyder corneal dystrophy.